Eastgate Biotech Corp. (ETBI)
OTCMKTS · Delayed Price · Currency is USD
0.0045
+0.0045 (449,900.00%)
At close: Apr 10, 2025

Eastgate Biotech Income Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
TTM FY 2016 FY 2015 FY 2014 FY 2013 FY 2012 2007 - 2011
Period Ending
Sep '17 Dec '16 Dec '15 Dec '14 Dec '13 Dec '12 2007 - 2011
Revenue
0.14-0.13---
Upgrade
Cost of Revenue
0.15-0.02---
Upgrade
Gross Profit
-0.01-0.11---
Upgrade
Selling, General & Admin
3.242.133.173.981.520.5
Upgrade
Research & Development
0.380.51.120.840.130.11
Upgrade
Operating Expenses
3.622.634.284.821.660.61
Upgrade
Operating Income
-3.63-2.63-4.17-4.82-1.66-0.61
Upgrade
Interest Expense
-0.24-0.16-0.11-0.09-0.06-0.02
Upgrade
EBT Excluding Unusual Items
-3.87-2.79-4.28-4.91-1.72-0.62
Upgrade
Asset Writedown
--0.18----
Upgrade
Pretax Income
-3.82-2.98-4.28-4.91-1.72-0.62
Upgrade
Net Income
-3.82-2.98-4.28-4.91-1.72-0.62
Upgrade
Net Income to Common
-3.82-2.98-4.28-4.91-1.72-0.62
Upgrade
Shares Outstanding (Basic)
558305192503224
Upgrade
Shares Outstanding (Diluted)
558305192503224
Upgrade
Shares Change (YoY)
87.04%59.16%286.67%56.60%32.51%105.29%
Upgrade
EPS (Basic)
-0.01-0.01-0.02-0.10-0.05-0.03
Upgrade
EPS (Diluted)
-0.01-0.01-0.02-0.10-0.05-0.03
Upgrade
Free Cash Flow
-1.81-0.39-0.57-1.34-0.43-
Upgrade
Free Cash Flow Per Share
-0.00-0.00-0.00-0.03-0.01-
Upgrade
Gross Margin
-8.46%-85.46%---
Upgrade
Operating Margin
-2640.79%--3159.54%---
Upgrade
Profit Margin
-2774.35%--3242.80%---
Upgrade
Free Cash Flow Margin
-1314.10%--430.56%---
Upgrade
EBITDA
-3.55-2.58-4.13-4.79-1.64-
Upgrade
D&A For EBITDA
0.090.050.040.030.01-
Upgrade
EBIT
-3.63-2.63-4.17-4.82-1.66-0.61
Upgrade
Updated Mar 4, 2019. Source: S&P Global Market Intelligence. Standard template. Financial Sources.